News
RGEN
163.86
-1.64%
-2.73
Weekly Report: what happened at RGEN last week (1222-1226)?
Weekly Report · 12/29/2025 10:10
Is Repligen (RGEN) Quietly Recasting Its Gene Therapy Moat With New HiPer Viral Vector Resins?
Simply Wall St · 12/25/2025 01:28
Adaptive Biotechnologies is the top performing life sciences tools and services stock YTD
Seeking Alpha · 12/23/2025 05:06
3 Stocks Estimated To Be Trading Below Their Intrinsic Value In December 2025
Simply Wall St · 12/22/2025 17:08
Weekly Report: what happened at RGEN last week (1215-1219)?
Weekly Report · 12/22/2025 10:09
Repligen (RGEN): Assessing Valuation After New Chromatography Resins Expand Its Gene Therapy Toolkit
Simply Wall St · 12/19/2025 05:21
Insider Move at Repligen Sparks Fresh Buzz on Wall Street
TipRanks · 12/19/2025 02:06
Repligen Director Karen A. Dawes Reports Sale of Common Shares
Reuters · 12/18/2025 21:31
Repligen Corporation to Present at J.P. Morgan Healthcare Conference
Reuters · 12/18/2025 12:30
Repligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference
Barchart · 12/18/2025 06:30
The Bull Case For Repligen (RGEN) Could Change Following New Gene Therapy Chromatography Resin Launches
Simply Wall St · 12/16/2025 22:16
Analysts Conflicted on These Healthcare Names: Pfizer (PFE), Novan (NOVN) and Repligen (RGEN)
TipRanks · 12/16/2025 14:50
J.P. Morgan Keeps Their Buy Rating on Repligen (RGEN)
TipRanks · 12/16/2025 14:17
Repligen announces launch of three high-performance resins
TipRanks · 12/16/2025 12:35
Repligen Unveils Next-Generation Chromatography Resins
Reuters · 12/16/2025 12:30
Repligen Introduces Next-Generation Chromatography Resins to Advance New Modality Workflows
Barchart · 12/16/2025 06:30
Repligen Is Maintained at Overweight by Barclays
Dow Jones · 12/15/2025 21:18
Repligen Price Target Raised to $200.00/Share From $175.00 by Barclays
Dow Jones · 12/15/2025 21:18
Barclays Maintains Overweight on Repligen, Raises Price Target to $200
Benzinga · 12/15/2025 21:07
Repligen Is Maintained at Overweight by Wells Fargo
Dow Jones · 12/15/2025 18:39
More
Webull provides a variety of real-time RGEN stock news. You can receive the latest news about Repligen through multiple platforms. This information may help you make smarter investment decisions.
About RGEN
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.